FDA Peptide Tracker

TRT / Enclomiphene: live FDA regulatory status

Testosterone hormone therapy · Hormone

The two signals

Plain-English verdict: amber.

Regulatory status: 503A eligible · SKU pending.

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Join waitlist

What happens next

Fulfillment confirmation (pending) — 2026

Regulatory timeline

TRT / Enclomiphene: common questions

Is enclomiphene legal in 2026?
Enclomiphene is 503A eligible, so the compounding pathway exists. Our own SKU is not live yet, which is a fulfillment question rather than a legal one — and we would rather say which is which.
Can I get TRT or enclomiphene from Peptós.LIFE right now?
Not yet. This is waitlist-only while fulfillment is confirmed. Nothing is transactable during the founding period.
Is compounded enclomiphene FDA-approved?
No. Compounded medications are prepared for an individual patient and are not FDA-approved. Any hormone protocol requires a US-licensed clinician to review your bloodwork and decide, and we will not route around that.
What happens next for TRT / enclomiphene?
Fulfillment confirmation, expected in 2026. We will move the verdict the day we can actually fill a prescription, not before.

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board.

Embed this card on your site · free, CC BY 4.0, no key.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.